My central claim challenges what most people assume about aging tissue. The age-related decline in senescent cell function isn't the core problem—younger cells lose their ability to read and respond to senescent signals through the ERK pathway. When target cells get constantly bombarded with SASP factors, their receptors become desensitized and downstream ERK signaling goes awry. These receiving cells essentially become functionally deaf to signals that young senescent cells still transmit just fine. That's the same defect seen in aged senescent cells themselves: nuclear ERK retention problems.

The paper showed that aged cells can't keep ERK in the nucleus because of excessive negative feedback from DUSPs and the PEA-15 export system. I think target cells experience something similar but different—chronic IL-8 and HGF receptor activation triggers ERK-dependent feedback loops that gradually dampen signaling capacity. This would explain why young senescent fibroblasts still drive pro-regenerative programs while aged tissue sits there unresponsive. The flaw isn't in sending the signal; it's in receiving it.

This reframes the senolytic paradox nicely. Clearing senescent cells eliminates a signal source that younger cells can no longer decode anyway. But here's the thing—selective ERK pathway modulators acting on the receiving compartment could potentially restore tissue responsiveness without wiping out the tumor-suppressive OIS barrier that senescent cells provide.

A few testable predictions follow from this. First, young fibroblasts cultured with SASP-conditioned media for a week or more should show reduced nuclear ERK retention and a blunted proliferative response to fresh SASP, essentially mimicking aged cell kinetics. Second, primary dermal fibroblasts from young donors will display decreased ERK nuclear localization after repeated SASP exposure—this should be reversible by knocking down DUSP1. Third, aged mice with wounds ought to heal better when treated with low-dose MEK inhibitors that normalize ERK dynamics in receiving cells, not with senolytic drugs that deplete the SASP source.

The falsifiability test is straightforward. If young target cells maintain normal ERK kinetics and SASP responsiveness despite chronic exposure, and if senolytic clearance consistently improves tissue function across contexts without creating tumor risks, the hypothesis falls apart. But the model predicts senolytics will show context-dependent harms—impaired wound healing, lost tumor surveillance—that ERK-targeted approaches would avoid.